Contact dermatitis · 2012
The detection of clinically relevant contact allergens with a standard screening tray of 28 allergens.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Patel Devika, Belsito Donald V
Аннотация
BACKGROUND: A standard method for diagnosing allergic contact dermatitis in the United States is the thin-layer rapid use epicutaneous (TRUE) test (TRUE Test™), which consists of three panels containing 20 individual allergens and eight allergen mixes. Previous studies had raised concern regarding the adequacy of the initial two-panel TRUE Test™ system (16 individual allergens and seven allergen mixes) in fully assessing patients with possible allergic contact dermatitis.
OBJECTIVES: We sought to investigate the effectiveness of the current three-panel TRUE Test™ as the sole diagnostic tool for detecting allergic contact dermatitis.
PATIENTS/MATERIALS/METHODS: This study was a retrospective analysis of 2088 patients who underwent patch testing between 1995 and 2010. Study groups were analysed to determine whether positive reactions were to allergens and/or mixes present in the TRUE Test™ panels.
RESULTS: Of the 2088 patch-tested patients, 1385 had at least one positive reaction. Among these 1385 patients, 27.6% were fully evaluated by use of only the TRUE Test™ series, 49.9% were partially evaluated, and 22.5% did not have any of their allergens detected. On assessment for clinical relevance, similar percentages were observed.
CONCLUSION: In our study, the current TRUE Test™ series of 28 allergens would have completely identified allergens in only 27.6% of patients. Broadening the standard panel to include common allergens causing >50% of allergic contact dermatitis cases in a given geographical location and aim testing allergens on the basis of the patient's history will increase the test's sensitivity.
OBJECTIVES: We sought to investigate the effectiveness of the current three-panel TRUE Test™ as the sole diagnostic tool for detecting allergic contact dermatitis.
PATIENTS/MATERIALS/METHODS: This study was a retrospective analysis of 2088 patients who underwent patch testing between 1995 and 2010. Study groups were analysed to determine whether positive reactions were to allergens and/or mixes present in the TRUE Test™ panels.
RESULTS: Of the 2088 patch-tested patients, 1385 had at least one positive reaction. Among these 1385 patients, 27.6% were fully evaluated by use of only the TRUE Test™ series, 49.9% were partially evaluated, and 22.5% did not have any of their allergens detected. On assessment for clinical relevance, similar percentages were observed.
CONCLUSION: In our study, the current TRUE Test™ series of 28 allergens would have completely identified allergens in only 27.6% of patients. Broadening the standard panel to include common allergens causing >50% of allergic contact dermatitis cases in a given geographical location and aim testing allergens on the basis of the patient's history will increase the test's sensitivity.